Cargando…
Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice
Dipeptidyl-peptidase 4 (DPP-4) inhibitor (sitagliptin) is a novel anti-hyperglycemia drug in the treatment of type 2 diabetes. However, its potential in type 1 diabetes is still unclear. Recent studies show that increased infection, especially respiratory tract infection, is significantly associated...
Autores principales: | He, Xinran, Li, Wangen, Xie, Yunliang, Zhao, Yunjuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510641/ https://www.ncbi.nlm.nih.gov/pubmed/33182020 http://dx.doi.org/10.1016/j.intimp.2020.106945 |
Ejemplares similares
-
Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation
por: Kim, Su-Jin, et al.
Publicado: (2009) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
por: Tian, Yu, et al.
Publicado: (2023) -
Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation
por: Juang, Jyuhn-Huarng, et al.
Publicado: (2014) -
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)